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Monoclonal extramedullary plasmacytoma (EMP) is a rare plasma cell tumor. The dilagnosis is based on a mass of clonal plasma 
cells separate from bone or bone marrow without evil
dence of occult disease elsewhere. It occurs in the upper 
aerodigestive tract in more than 80% of patients, most 
often in the nasal cavity, paranasal sinuses, nasopharynx, 
oropharynx and larynx.1,2 Regional nodes are invaded in 
less than 10% of patients.1 The disease is more coml
mon in males with a peak incidence in the sixth decade. 
Primary EMP often presents with a mass and produces 
local compressive symptoms. The differential diagnosis 
includes benign reactive processes, carcinoma and lyml
phoma. Radiotherapy (RT) is an effective modality of 
treatment for EMP with high local control rates (85% 
to 100%).1,3l6 Currently moderate dose RT (40l50 Gy) 
using involved fields is recommended. 
CASe
A 76lyearlold man presented with a 5lmonth history 
of painful swallowing. He was a farmer and his past 
medical history included hypertension and a coronary 
bypass. He was a nonlsmoker. At the time of presenl
tation he was experiencing partial airway obstruction. 
Endoscopically, a tumoral mass approximately 4 cm in 
diameter reaching to the left tonsillar region and lingual 
epiglottis from the tongue base was detected. Physical 
examination revealed a mobile, single 3lcm asymptoml
atic left cervical midjugular lymph node. MR imaging 
demonstrated a solid submucosal mass, measuring 
4×4.5×7 cm, in the tongue base and left tonsil which 
partially obstructed the oropharyngeal airway (Figure 
1). Additionally, post GdlDTPA T1lweighted coronal 
MR image showed deep cervical bilateral lymph nodes. 
The mass and nodes showed a strong contrast enhancel
ment. Clinically, this lesion suggested squamous cell 
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carcinoma or malignant lymphoma. Histopathological 
analysis of the biopsy revealed a diffuse infiltration of 
atypical plasma cells beneath the surface epithelium. 
Plasma cells had a prominent eccentric nucleus with a 
“spoke wheel” chromatin and abundant basophilic cytol
plasm (Figure 2). Immunohistochemical study showed 
diffuse cytoplasmic and focal membranous CD138 
(Syndecanl1, Clone 5F7, LabVision, Fremont, CA) and 
cytoplasmic CD79a (DAKO, Copenhagen, Denmark) 
immunoreactivity (Figure 3a and 3b). Focal membral
Figure 1. Coronal post-Gd-DTpa T1-weighted image showing 
multilobulated lesions with well-defined borders occupying 
the left tonsillar fossa and causing a partially obstructed 
oropharyngeal airway.
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Figure 2. plasma cells with eccentric nucleus and abundant cytoplasm (hematoxylin 
eosin ×400).
Figure 3. a) Diffuse cytoplasmic, focal membranous (arrows) CD138 staining on the plasma cells (streptavidine-
biotin peroxidase ×400). b) CD79a positivity on the majority of the neoplastic plasma cells (streptavidine-biotin 
peroxidase ×400). c) λ-light chain positivity with lack of κ-staining.d) Note the scattered reactive plasma cells 
(arrows) on the anti κ-immunostaining (streptavidine-biotin peroxidase ×100, ×200).
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nous EMA (DAKO, Copenhagen, Denmark) positivity 
with lack of CD20 (Clone L26, LabVision, Fremont, 
CA) staining were detected on the neoplastic plasma 
cells. Diffuse strong γllight chain (clone HP6054, 
LabVision, Fremont, CA), expression was detected 
whereas only scattered plasma cells were positive with 
anti κlantibody (Clone L1C1, LabVision, Fremont, 
CA) (Figure 3c and 3d). Based on these findings, the 
tumor was diagnosed as a plasmacytoma.
He was referred to the hematologists. Further clinil
cal examinations were performed to rule out multiple 
myeloma (MM). Quantitative immunoglobulins, full 
blood count, urea, calcium, creatinine, and βl2lmicrol
globulin were all within normal ranges. No histological 
evidence of bone marrow involvement and distant bone 
lesions on radiological skeletal survey were detected. In 
serum protein electrophoresis, a high level of αl2 globl
uline and in urine analysis, proteinuria and high level of 
lambda light chain (6.24 mg/dL) were detected. After 
ruling out MM, the patient was diagnosed as having 
EMP of the oropharynx, which is of unknown origin.
Because of the morbidity of the surgery, the patient 
was subsequently treated with steroids and external 
beam radiotherapy at a dose of 50 Gy in 25 fractions 
with cobaltl60 gamma rays to involved sites (oropharl
ynx and bilateral level IblV cervical nodes) with a threel
field technique (one anterior and two lateral opposing 
fields). At the end of the treatment, there was tumor 
response and the patient was symptom free. Three 
months after the treatment, a partial response (a 75% 
reduction in size of tumor) and a complete response in 
the nodes were detected on MR image (Figure 4). On 
the left tonsillar site a remnant tumoral mass (2×1.5 
cm) remained. All blood and urine tests were normal. 
The patient died of an intercurrent disease at 15 months 
from the diagnosis with no evidence of disease.
DISCUSSIOn
EMP is a plasma cell neoplasm of the soft tissue. It is 
usually well localized, with 80% of them occurring in 
the submucosa of the upper aerodigestive tract.2 The 
most common locations for an EMP to occur are the 
nasal cavity, paranasal sinuses, nasopharynx and orol
pharynx. The predisposition of this pathology for the 
submucosa of the upper respiratory tract has led to the 
hypothesis that chronic stimulation by inhaled irritants 
or viruses may promote the development of plasmacyl
toma.7 In our patient, he had worked as a farmer for 
55 years and might have been exposed to agricultural 
inhaled irritants for a long time since EMP appears as 
a slowly growing mass and the diagnosis is commonly 
delayed. Huge tumoral masses preclude the origin of 
the tumor; therefore, it may not be defined until the 
treatment is completed. At the beginning, the origin of 
the tumor in the presented case was reported as the left 
tonsillar site or base of the tongue. However, 3 months 
after treatment a remnant tumoral mass was detected 
on the left tonsil on MR image. The base of the tongue 
and the left tonsil were considered as one tumor.
EMP involving the tonsillar site is rare. Alexiou et 
al reported that 82.2% of 869 cases of EMP described 
in the literature were found in the upper aerodigestive 
tract, and 17.8% of EMPs arising in the upper aerodil
gestive tract were in the oropharynx.1 To date, there 
have been 11 reported cases of tonsillar plasmacytoma 
in the series of head and neck EMPs and as case reports 
in the English medical literature.4,8l11 They were treated 
predominantly with surgery and radiotherapy giving a 
median dose of 40 Gy to the tumor and regional nodes. 
Local control was achieved in all patients. In the present 
case, the patient was treated only with RT at the dose of 
50 Gy and local control was achieved.
Histologically, plasmacytomas have the typical mil
croscopic appearance of a monomorphic plasma cell 
infiltrate set in a sparse, delicate, and reticular stroma. 
Figure 4. Three months after the treatment coronal post Gd-DTpa dynamic image shows 
a remnant tumoral mass on the left tonsillar site. 
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The plasma cells themselves are characterized by round 
eccentric nuclei. One type of Ig light chainleither kappa 
or lambda is detected by immunohistochemical stainl
ing.11 The differential diagnosis includes benign reactive 
inflammatory processes, squamouslcell carcinoma and 
lymphoma.2 In the presented case, the presence of an 
epithelial tumor was excluded easily by the morphol
logical assessment of the biopsy. Diffuse plasma cell 
infiltrate and monoclonality detected by the immunol
histochemical staining directed us to rule out a benign 
reactive process in the differential diagnosis. Another 
main entity that we considered in the differential diagl
nosis is the plasmacytic differentiation of nonlHodgkin 
lymphoma. Plasmacytic differentiation of a marginal 
zone lymphoma and lymphoplasmacytic lymphoma 
was excluded by negativity of CD20 immunostaining. 
Plasmacytic differentiation is less commonly seen in 
other Blcell lymphomas, including small lymphocytic 
lymphoma and diffuse large Blcell lymphoma.12l15 In 
the present case, the uniformity of plasma cells and the 
immunohistochemical findings strongly supported a 
plasmacytoma. 
Although levels are lower than the ones in MM, 
onelthird of cases of EMP show a monoclonal band 
of serum protein at diagnosis and BencelJones protein 
is rarely seen in the urine.16 The presence of monoclol
nality did not predict the development of MM. These 
markers usually return to normal ranges after successl
ful treatment of the primary disease.11 The presence of 
paraprotein at diagnosis but not its persistence may be 
an important indicator of dissemination of EMP. It was 
not possible, however, to analyze this relationship in a 
rigorous way because of the small number of cases with 
paraprotein at diagnosis. In our case, there was a high 
level of lambda light chain in urinalysis. Three months 
after the treatment, the markers had returned to normal 
ranges. 
Because of the proven radiosensitivity of the disease, 
RT plays a main role in the treatment of EMP. No conl
clusive data have been published on the optimal radial
tion dose for EMP. Many authors have reported a wide 
range of doses varying from 30 to 66 Gy.6,17,18 Although 
some studies reported no doselresponse relationship in 
RT for plasmacytomas,17,19 the others suggested that 
45l50 Gy is necessary for a high local control rate.3,10 
Mendenhall et al reported that for the patients treated 
with ≥40 Gy of radiation, there was only 6% incidence 
of local failure, which was superior to 31% for those 
who received <40 Gy.16 A higher dose (up to 50 Gy 
in 25 fractions) was recommended for bulky disease 
(>5 cm).3,11,18,19 In our case, a dose of 50 Gy was given 
because of a bulky tumor. Regression could be slower 
than expected, with the complete response occurring 
within 12 months after completion of treatment.6 In the 
presented case, 3 months after the treatment, a partial 
response was detected on tumor and a year after treatl
ment a complete response was detected on MR image.
The other important issue related to RT is the necesl
sity of elective regional lymph node irradiation (ENI). 
Cervical node metastases varies from 7% to 30% for 
EMP at the time of diagnosis.1,10,11,16 Some authors rel
ported a relatively high rate of outlfield nodal relapse, 
up to 18% and do recommend ENI.3,6 Others present 
a negligible risk for nodal relapse of up to a maximum 
4% so do not recommend ENI.4,5,11 However, a third 
group of authors recommend a selective approach, with 
regional node irradiation to be implemented only in the 
case of bulky local disease or primaries originating from 
sites with rich lymphatic network (i.e., the oral cavity, 
oropharynx, nasopharynx and supraglottic larynx).4,10,11 
In our case, because of the localization of the tumor and 
the presence of nodal involvement, cervical node regions 
(level IblV) were irradiated. 
In summary, the diagnosis of EMP depends on spel
cific histologic and immunohistochemical examination 
of the lesion, as well as a thorough search of the body 
to exclude MM. MRI is a useful method in evaluating 
the response to treatment and during the followlup pel
riod. The role of surgery should be limited to biopsy, 
small resectable tumors and locoregional recurrences. 
Radiotherapy is an effective modality of treatment for 
EMP with high local control rates. Moderate dose RT 
(40l50 Gy) using limited fields encompassing the pril
mary tumor and first echelon lymph nodes with primal
ries originating from sites with a rich lymphatic network 
is recommended. 
case reporteXTRameDullaRy plaSmaCyTOma
Hematol Oncol Stem Cell Ther 1(4)     October 2008 hemoncstem.edmgr.com 245
1. alexiou C, Kau RJ, Dietzfelbinger H, Kremer m, 
Spiess JC, Schratzenstaller B, et al. extramedul-
lary plasmacytoma: tumor occurrence and thera-
peutic concepts. Cancer. 1999;85:2305-2314.
2. Kapadia SB, Desai u, Cheng VS. extramedul-
lary plasmacytoma of the head and neck: a clini-
copathologic study of 20 cases. medicine (Balti-
more). 1982;61:317-329.
3. mayr Na, Wen BC, Hussey DH, Burns Cp, Sta-
ples JJ, Doornbos JF, et al. The role of radiation 
therapy in the treatment of solitary plasmacyto-
mas. Radiother Oncol. 1990;17:293-303.
4. Chao mW, Gibbs p, Wirth a, Quong G, Guiney 
mJ, liew KH. Radiotherapy in the management of 
solitary extramedullary plasmacytoma. intern med 
J. 2005;35:211-215.
5. michalaki VJ, Hall J, Henk Jm, Nutting Cm, Har-
rington KJ. Definitive radiotherapy for extramedul-
lary plasmacytomas of the head and neck. Br J 
Radiol. 2003;76:738-741. 
6. Bolek TW, marcus RB, mendenhall Np. Solitary 
plasmacytoma of bone and soft tissue. int J Radiat 
Oncol Biol phys. 1996;36:329-333.
7. Wiltshaw e. The natural history of extramed-
ullary plasmacytoma and its relation to solitary 
myeloma of bone and myelomatosis. medicine 
(Baltimore). 1976;55:217-238.
8. Sakai y, ikeya J, morita i, Sato K. extramedul-
lary plasmacytoma of the tonsil diagnosed by 
fine-needle aspiration cytology. ann Diagn pathol. 
2008;12:41-43.
9. Galieni p, Cavo m, pulsoni a, avvisati G, Bigazzi 
C, Neri S, et al. Clinical outcome of extramedullary 
plasmacytoma. Haematologica. 2000;85:47-51.
10. liebross RH, Ha CS, Cox JD, Weber D, Dela-
salle K, alexanian R. Clinical course of solitary 
extramedullary plasmacytoma. Radiother Oncol. 
1999;52:245-249.
11. Strojan p, Soba e, lamovec J, munda a. ex-
tramedullary plasmacytoma: Clinical and histo-
pathologic study. int J Radiat Oncol Biol phys. 
2002;53:692-701.
12. Van Huyen Jp, molina T, Delmer a, audouin J, 
le Tourneau a, Zittoun R, et al. Splenic marginal 
zone lymphoma with or without plasmacytic differ-
entiation. am J Surg pathol. 2000;24:1581-1592.
13. lin p, medeiros lJ. lymphoplasmacytic lym-
phoma / Waldenström macroglobulinemia: an 
evolving concept. adv anat pathol. 2005;12:246-
255.
14. evan Hl, polski Jm, Deshpande V, Dunphy CH. 
CD5+ true Sll/Cll with plasmacytic differentia-
tion and an unusual 1p36 translocation: case re-
port and review of the literature. leuk lymphoma. 
2000;39:625-632.
15. Teruya-Feldstein J. Diffuse large B-cell lym-
phomas with plasmablastic differentiation. Curr 
Oncol Rep. 2005;7:357-363.
16. mendenhall Cm, Thar Tl, million RR. Solitary 
plasmacytoma of bone and soft tissue. int J Radiat 
Oncol Biol phys. 1980;6:1497-1501.
17. Ozsahin m, Tsang RW, poortmans p, Belkacémi 
y, Bolla m, Dinçbas FO, et al. Outcomes and pat-
terns of failure in solitary plasmacytoma: a multi-
center Rare Cancer Network study of 258 patients. 
int J Radiat Oncol Biol phys. 2006;64:210-217.
18. Tsang RW, Gospodarowicz mK, pintilie m, 
Bezjak a, Wells W, Hodgson DC, et al. Solitary 
plasmacytoma treated with radiotherapy: impact 
of tumor size on outcome. int J Radiat Oncol Biol 
phys. 2001;50:113-120.
19. Holland J, Trenkner Da, Wasserman TH, Fine-
berg B. plasmacytoma. Treatment results and 
conversion to myeloma. Cancer. 1992;69:1513-
1517.
RefeRenCeS
